AML

In an interview with Targeted Oncology, Jorge Cortes, MD, highlights the use of olutasidenib in patients with relapsed/refractory acute myeloid leukemia.

The phase 1 study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of KT-253 monotherapy in patients with acute myeloid leukemias.

A time-based pathway to final analysis has been cleared by the FDA to evaluate the effect of uproleselan on relapsed/refractory acute myeloid leukemia.

Following a report of a serious grade 5 adverse event, the phase 1 PLAT-08 trial of SC-DARIC33 in pediatric patients with acute myeloid leukemia has been placed on hold

Sheng F. Cai, MD, PhD, discusses the results of the BEAT AML master trial in patients with acute myeloid leukemia.

Mark J. Levis, MD, PhD, discusses the takeaways from the phase 3 BMT CTN 1506/MORPHO trial which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD–positive acute myeloid leukemia.

In patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease after hematopoietic stem cell transplant, treatment with gilteritinib elicited a 48% reduction vs patients without detectable MRD.

The KMT2A inhibitor appeared safe and led to clinical activity in the treatment of patients with NPM1-mutated, relapsed/refractory acute myeloid leukemia, according to the phase 1 KOMET-001 trial.

Now that the FDA has lifted the partial clinical hold on the phase 1 study of FHD-286 in patients with relapsed/refractory acute myelogenous leukemia and myelodysplastic syndrome, there are plans to initiate a trial to further assess the agent with decitabine or cytarabine.

When used as a monotherapy or in combination with venetoclax, voruciclib was generally well tolerated and showed an encouraging preliminary efficacy signal in patients with acute myeloid leukemia or B-cell malignancies.

Brian A. Jonas, MD, discusses studies investigating the use of uproleselan for the treatment of patients with acute myeloid leukemia.

Results from the phase 3 QuANTUM-First study create a position for quizartinib plus chemotherapy in the FLT3-ITD-positive acute myeloid leukemia armamentarium.

The new Prescription Drug User Fee Act action date for quizartinib for use in patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia has been set to July 24, 2023.

Eytan M. Stein, MD, provides community oncologists with an overview of the unmet needs in the acute myeloid leukemia space and provides recommendations for those treating patients with this disease.

The next-generation anthracycline Annamycin has been administered to the first patient with relapsed/refractory acute myeloid leukemia in combination with cytarabine in a phase 1/2 study.

One of the key tools used to detect leukemic cells is measurable residual disease, formerly referred to as minimal residual disease.

Courtney D. DiNardo, MD, MSCE, provided an overview of venetoclax resistance and interrelated mechanisms, with a spotlight on kinase signaling pathways, TP53 mutation, monocytic, and other forms of resistance.

The inaugural participant with AML showing a mutation of FLT3 in a relapsed/refractory form has been recruited into the Phase 1 FRIDA trial.

A patient who received AB8939, a microtubule inhibitor, in a phase 1 study, had a significant reduction in bone marrow blasts, showing its potential to treat drug-resistant acute myeloid leukemia.

Preclinical and phase 1/2a data evaluating the safety and tolerability of EP0042 in patients with relapsed or refractory acute myeloid leukemia has led the FDA to grant an orphan drug designation to the agent.

In an interview with Targeted Oncology, Brian A. Jonas, MD took a close look at the precision medicine landscape for AML and discussed key biomarkers and research needs for the future.

Brian A. Jonas, MD, PhD, discusses novel biomarkers being explored in acute myeloid leukemia, including e-selectin, which Jonas believes is very promising.

Early data of the Orca-T cellular therapy showed enough positive results from patients on the therapy to move on to a phase 3 study in this patient population.

The independent Data Monitoring Committee recommends the phase 3 study evaluating treatment with uproleselan in patients with relapsed/refractory acute myeloid leukemia to continue to the original planned final overall survival events trigger.

Patients with acute myeloid leukemia given annamycin demonstrated tolerable safety and preliminary efficacy with the agent, according to topline results from a phase 1/2 study.